The clinical management of metastatic melanoma has been changed by BRAF (BRAFi) and MEK inhibitors (MEKi), which represent a standard treatment for <i>BRAF</i>-mutant melanoma. The gene discussed is MAP2K7; the disease is metastatic melanoma.